Back to today’s briefing

Story perspectives

Inflation Act Sparks Debate Over Drug Pricing Reforms

5/2/2025

28 3

Summary

Story summary

The Inflation Reduction Act ignites controversy with its "pill penalty," enabling Medicare to negotiate small-molecule drug prices four years ahead of biologics. Industry leaders are pushing for reforms to enhance transparency and access. In a notable shift, CVS Caremark designates Wegovy as the go-to obesity treatment, highlighting the surging interest in GLP-1 medications.

1 of 1

Story summary

The Inflation Reduction Act ignites controversy with its "pill penalty," enabling Medicare to negotiate small-molecule drug prices four years ahead of biologics. Industry leaders are pushing for reforms to enhance transparency and access. In a notable shift, CVS Caremark designates Wegovy as the go-to obesity treatment, highlighting the surging interest in GLP-1 medications.